The treatment landscape and biological understanding of neuroendocrine tumors 
Introduction
Analysis of the Surveillance, Epidemiology, and End Results (SEER) database has suggested an increasing incidence of neuroendocrine tumors (NETs) from 1 VEGF-targeted therapy, may diminish resistance (8) .
Additional strategies to overcome these resistance mechanisms have been explored in animal models and in the clinical setting (9) . For example, studies in xenograft models have demonstrated that the combination of bevacizumab and HIF-1 or Sp1 inhibitors may increase the therapeutic efficacy of anti-angiogenic treatment (10, 11) . Co-targeting of VEGF and FGF signaling pathways has also been shown to improve efficacy and overcome adaptive resistance to VEGF inhibition in the RIPTag2 model of PanNETs (12) .
mTOR pathway
Mammalian target of rapamycin (mTOR) is the convergence hub of a variety of extracellular and intracellular signals. As a master regulator of different cell functions, mTOR activation is subjected to tight and coordinated regulations through diverse positive and feedback regulatory loops ( Figure 2 ) (13). Moreover, mTOR forms two distinct protein complexes, commonly referred as mTORC1 and mTORC2, which are activated in different ways and exert different but related functions (14) . Mutations in PanNET patients and demonstrated a significant increase in progression free survival (PFS) in patients receiving everolimus as compared with those receiving placebo (11 vs. 4.6 months), leading to its approval by the FDA and EMEA for this indication (18) . A parallel study in patients with advanced extrapancreatic NET/carcinoid also suggested that everolimus might have some activity, although the study did not meet its pre-defined efficacy endpoint (19) .
Everolimus is known to specifically inhibit mTORC1, although prolonged drugs exposure might impair mTORC2 activity in a cell-type specific manner. The 
Somatostatin receptor signaling
SST and its synthetic analogues (e.g. lanreotide, octreotide) act through a family of five G-protein couple receptors termed sst1-sst5 to exert a variety of functions, including inhibition of endocrine and exocrine secretions and of tumoral cell growth (26, 27) .
While SST analogs are associated with high symptomatic response rates initially, patients may develop resistance to treatment over time (28) (29) (30) . The molecular mechanisms underlying the development of resistance remain poorly understood. However, recent studies have identified a novel truncated sst5 receptor variants in rodents (31, 32) and humans (33) , which at variance with full-length canonical sst5, display selective responses to SST and cortistatin, and exhibit distinct tissue distribution and a unique subcellular localization. One variant, sst5TMD4, which is barely expressed in normal human tissues, shows a marked upregulation in tumors, where it appears to entail pathologically relevant functions.
Thus, for example, expression of sst5TMD4 in pituitary adenomas causing acromegaly is related to the reduced ability of octreotide at normalizing hormone secretion in poorly responsive tumors in vivo (34) . In breast cancer, the presence of sst5TMD4 (which is negligible in normal mammary gland) is associated with markers of poor prognosis (lower levels of ER, HER2/Neu and p53) and its expression in breast cancer model cell lines was shown to increase malignancy features (cell proliferation, signaling, invasiveness, and migration) by disrupting normal sst2 function (35) . Such observations suggest a potential role for these novel truncated receptor variants in tumor diagnosis as a prognostic marker and as therapeutic targets.
Target Discovery in Neuroendocrine Tumors

Sequencing efforts in NET
The recognition of driver oncogene mutations in a number of human cancers has provided a compelling rationale for targeted therapies (Table 1) (49) . Collectively, these observations point to a key role for menin in epigenetic regulation.
P53 and MDM2
The tumor suppressor p53 plays a critical role in maintaining genomic stability and tumor prevention (50) . The p53 pathway is tightly regulated by a number of proteins, 
protein via RB1 gene mutation is also frequently observed in poorly differentiated and high grade NETs (55) . Furthermore, growth of the human PanNET cell line QGP1 can be inhibited in a xenograft mouse model by the CDK4/6 specific inhibitor PD 0332991, which re-activates the Rb pathway (54) . Thus, gene amplification and overexpression of CDK4 and CDK6 suggest that a subset of patients with PanNETs may respond favorably to CDK4/6 inhibitors that are currently entering clinical trials.
Biomarker discovery in neuroendocrine tumors
Circulating tumor cells
The CellSearch™ platform for cancer detection, amongst other technologies, has CTCs are associated with progressive NETs and could be used as a prognostic marker (57) . In a prospective study of 120 patients with metastatic NETs, presence of CTCs conferred poorer overall survival with a hazard ratio of 14 (62) . 
Novel methods of biomarker analysis
Cancer companion diagnostics is a pathway-oriented approach to cancer analysis that integrates mutational analyses with protein activity biomarkers in clinical samples from patients treated with molecularly directed drugs. The goal is to develop diagnostics that better predict patient response to a drug and to create improved methods for monitoring therapy. Padlock probes, like selector probes, are highly 
Future Directions
The efficacy of VEGF pathway and mTOR inhibitors in NET suggests that the molecular characterization of VEGF and mTOR pathway components in NETs may shed light on predictive markers, as well as mechanisms by which treatment resistance can be overcome. The discovery that some SST receptors are truncated, resulting in aberrant signaling, suggests that more detailed examination of SST receptor status in tumor tissue may also offer the opportunity to tailor more selective and effective treatments. Re cer R cer r cer nc nc nc n n n a a a Ca Ca Ca C C C C C r r r fo fo fo an n Association f n n Association f n f an n n Association on an n n Associatio n n Associatio fo f n f f on an n n n Associatio A i ti i C C f f A i ti Anti-VEGF/R therapy Research.
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